{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:40:10Z","timestamp":1758973210663,"version":"3.44.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"am","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.annder.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T23:48:09Z","timestamp":1656028089000},"page":"264-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Delayed eczematous skin reaction as an adverse drug reaction to immunoglobulin infusions: A case series"],"prefix":"10.1016","volume":"149","author":[{"given":"C.","family":"Barthel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Musquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Veyrac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bernier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Hi\u00e9rarchisation des indications des immunoglobulines humaines polyvalentes en situation de forte tension d\u2019approvisionnement","author":"Adams","key":"10.1016\/j.annder.2022.05.002_bib0105"},{"key":"10.1016\/j.annder.2022.05.002_bib0110","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0755-4982(04)98888-4","article-title":"Immunomodulatory effects of intravenous immunoglobulins","volume":"33","author":"Guilpain","year":"1983","journal-title":"Presse Med"},{"key":"10.1016\/j.annder.2022.05.002_bib0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.annder.2022.05.002_bib0120","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.annder.2022.05.002_bib0125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000018259","article-title":"A Baboon syndrome induced by intravenous human immunoglobulins: Report of a case and immunological analysis","volume":"199","author":"Barbaud","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2022.05.002_bib0130","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0140-6736(87)90627-1","article-title":"Alopecia after immunoglobulin infusion","volume":"329","author":"Chan-Lam","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2022.05.002_bib0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/120347549800300209","article-title":"Lichenoid\/interface cutaneous eruptions to ivigs with the primary infusion may be related to the re-regulation of anti-idiotype network","volume":"3","author":"Smith","year":"1998","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.annder.2022.05.002_bib0140","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4065\/72.12.1151","article-title":"Intravenous immunoglobulin-induced lichenoid dermatitis: a unique adverse reaction","volume":"72","author":"Dietrich Yockey","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.annder.2022.05.002_bib0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00320024","article-title":"Erythema multiforme after intravenous immunoglobulin","volume":"56","author":"Rodeghiero","year":"1988","journal-title":"Blut"},{"key":"10.1016\/j.annder.2022.05.002_bib0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archderm.142.2.213","article-title":"Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature","volume":"142","author":"Vecchietti","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2022.05.002_bib0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaad.2010.12.034","article-title":"Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy","volume":"66","author":"Gerstenblith","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2022.05.002_bib0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejim.2008.04.022","article-title":"Intravenous immunoglobulins-induced eczematous eruption: a long-term follow-up study","volume":"20","author":"Cohen-Aubart","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.annder.2022.05.002_bib0165","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Therapy"},{"year":"2021","series-title":"Rule of nines. In: StatPearls [Internet]","author":"Moore","key":"10.1016\/j.annder.2022.05.002_bib0170"},{"key":"10.1016\/j.annder.2022.05.002_bib0175","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.53.5.1154","article-title":"Pompholyx (vesicular eczema) after IV immunoglobulin therapy for neurologic disease","volume":"53","author":"Iannaccone","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.annder.2022.05.002_bib0180","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.50.5.1273","article-title":"Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis","volume":"50","author":"Sorensen","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.annder.2022.05.002_bib0185","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1212\/WNL.54.9.1879","article-title":"Pompholyx after IV immunoglobulin therapy for neurologic disease","volume":"54","author":"Ikeda","year":"2000","journal-title":"Neurology."},{"key":"10.1016\/j.annder.2022.05.002_bib0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1398-9995.2005.00937.x","article-title":"Vesicular and bullous eczema in response to intravenous immunoglobulins","volume":"61","author":"Maetzke","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2022.05.002_bib0195","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/bmj.313.7069.1399c","article-title":"Intravenous immunoglobulin in the Guillain-Barr\u00e9 syndrome may cause severe adverse skin reactions","volume":"313","author":"Hamdalla","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.annder.2022.05.002_bib0200","first-page":"337","article-title":"Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy","volume":"2","author":"Uyttendaele","year":"2003","journal-title":"J Drugs Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963822000564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963822000564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:10:57Z","timestamp":1758971457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963822000564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0151963822000564"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2022.05.002","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed eczematous skin reaction as an adverse drug reaction to immunoglobulin infusions: A case series","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}